Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib. - ppt video online download
E-Learning Metastatic Melanoma Treatment
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma - Sarah J. Welsh, Pippa G. Corrie, 2015
PDF) Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAFv600e mutated melanoma cells in vitro
Drug-Like Small Molecules That Inhibit Expression of the Oncogenic MicroRNA-21 | ACS Chemical Biology
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma - Sarah J. Welsh, Pippa G. Corrie, 2015
Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy - ScienceDirect
PDF) Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis
Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma | Future Oncology
E-Learning Metastatic Melanoma Treatment
Dabrafenib in the treatment of metastatic or unresectable melanoma
Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma | Future Oncology
E-Learning Metastatic Melanoma Treatment
NCI 8628: A randomized phase 2 study of zivâ•'aflibercept and highâ•'dose interleukin 2 or highâ•'dose interleuki
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. - Abstract - Europe PMC
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis - ScienceDirect
PDF) Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma - Sarah J. Welsh, Pippa G. Corrie, 2015
Two Year Estimate of Overall Survival in COMBI-v, a Randomized, Open-Label, Phase 3 Study Comparing the Combination of Dabrafenib and Trametinib With Vemurafenib. - ppt video online download
PDF) Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAFv600e mutated melanoma cells in vitro
The Future of Melanoma Therapy
PDF) A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma
ECC 2015 - ecancer
Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy - ScienceDirect
Major Changes in Systemic Therapy for Advanced Melanoma
